FOLH1 and neoplasm: The new series of tracers was evaluated in vitro (IC50, binding to and internalization into LNCaP cells, binding to human serum albumin [HSA]) and in vivo (LNCaP tumor–bearing severe combined immunodeficiency [SCID] mice) and compared with the best recently described 18F-labeled PSMA inhibitors DCFPyL and PSMA-1007 (26,27).